Rui Yang is an experienced scientist with a strong background in genetics and immunology. As a Postdoctoral Researcher at the University of Southern California from September 2019 to February 2023, Rui Yang developed a novel transgenic mouse model for profiling interorgan communication and employed CRISPR-Cas9 technology to investigate transcription factors influencing the survival of CD19-targeted CAR-T cells. Currently serving as Scientist II at Nurix Therapeutics since July 2023, Rui Yang conducts potency assays on tumor-infiltrated lymphocytes to enhance adoptive cell therapy products and employs advanced multiomics analysis. Rui Yang also has postdoctoral experience at Peking University, where tumor-reactive and bystander CD8+ TILs were analyzed from human colorectal cancer samples. Academic qualifications include a PhD in Genetics from Tsinghua University and a visiting scholar program in Developmental Biology at Washington University in St. Louis.
This person is not in the org chart
This person is not in any teams
This person is not in any offices